Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1994-12-20
2000-06-06
Wortman, Donna
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241541, 4241551, 4241731, 4241741, 5303873, 5303882, 5303883, 5303888, 435328, A61K 39395
Patent
active
060715170
ABSTRACT:
Bispecific molecules which react both with the high-affinity Fc.gamma. receptor of human effector cells and with a target cell surface antigen are disclosed. Binding of the molecules to the Fc receptors found on effector cells is not blocked by human immunoglobulin G. The molecules are useful for targeting human effector cells (e.g. macrophages) against cells bearing the target antigen. For this purpose, bispecific molecules can be constructed containing the binding region derived from an anti-Fc.gamma. receptor antibody and the binding region derived from an antibody specific for the target antigen. Targeted effector cells can be used to destroy cells bearing the target cell surface antigen by cell-mediated antibody dependent cytolysis and by complement-fixation.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4954617 (1990-09-01), Fanger et al.
Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G.sub.1 Fragments," Science 229:81-83, Jul. 5, 1985.
Dillman, R.O., "Monoclonal Antibodies for Treating Cancer," Annals Int. Med 111:592-602, Oct. 1, 1989.
Hird et al., "Immunotherapy with Monoclonal Antibodies," in Genes and Cancer, Carney et al. Eds., Wiley & Sons, 1990.
Clark et al. (1990) in Bispecific Antibodies and Targeted Cellular Cytotoxicity (Romet-Lemonne et al., eds.) Fondation Nationale de Transfusion Sanguine, Les Ulis, France pp. 243-247.
de Leij et al. (1990) in Bispecific Antibodies and Targeted Cellular Cytotoxicity (Romet-Lemonne et al., eds.) Fondation Nationale de Transfusion Sanguine, Les Ulis, France pp. 249-253.
Nitta et al. (Feb. 17, 1990) The Lancet pp. 368-371.
Ball et al. (1992) J. Hematotherapy 1:85-94.
Anderson et al., J. Biol. Chem. 261:12856 (1986).
Shen et al., J. Immunol. 137:3378-3382 (1986).
Karpovsky et al., J. Exp. Med. 160:1686-1701 (1984).
Ball et al., J. Immun. 130:2937-2941 (1983).
Waldmann, T.A., "Monoclonal Antibodies in Diagnosis and Therapy," Science 252:1657-1662, Jun. 21, 1991.
Shen, et al., "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes That Is Enhanced by Interferon-.gamma. and is not Blocked by Human IgG," J. Immunol. 137:3378-3382, 1986.
Karpovsky et al., "Production of Target Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc.gamma. Receptor Antibodies," J. Exp. Med. 160:1686-1701, 1984.
Anderson et al., "Monoclonal Antibodies to Fc Receptors for IgG on Human Mononuclear Phagocytes," J. Biol. Chem. 261:12856-12864, 1986.
Ball et al., "A Unique Antigen Expressed On Myeloid Cells and Acute Leukemia Blast Cells Defined by a Monoclonal Antibody," J. Immunol. 130:2937-2941, 1983.
Ball Edward D.
Fanger Michael W.
Guyre Paul M.
DeConti, Jr. Guilio A.
Medarex Inc.
Remillard Jane E.
Wortman Donna
LandOfFree
Bispecific heteroantibodies with dual effector functions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific heteroantibodies with dual effector functions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific heteroantibodies with dual effector functions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2211192